Scholars Central

Conference abstractPublished 5 Dec 2018

Exploring potential of di-organotin Schiff base compounds as anti-cancer agents

Authors: Navjot S Batth

GHG Khalsa College, India

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

To explore the therapeutic potential of organotin compounds, Biogenic α-amino acids were utilized for in-situ generation of chiral Schiff base on di-butyltin oxide template conceiving six 1-6 optically pure organotin (IV) compounds. 1-6 were isolated, characterized by FTIR, NMR (1H, 13C, 119Sn) spectroscopy, mass spectrometry and elemental analyses. Single crystal X-ray diffraction of 1, 4 and 6 confirmed the monomeric structure in solid state, 1 and 4 were found to be enantiomerically pure contrary to 5, which crystallized in form of enantiomeric pair. In photophysical experiments, 1-6 emitted blue-violet fluorescence emission when excited by UV-radiation of wavelength 365 nm. The treatment of HeLa cell lines with different proportions of 1-6 revealed the compounds to be highly effective anti-cancer probes possessing high toxicity. The fluorescent nature of 1-6 prompted their use as potential bio-imaging agents. Confocal fluorescent microscopy of HeLa cells revealed the uptake of 1-6 inside HeLa cells, with higher concentrations were found in cytoplasm. The biological potential of these diorganotin compounds showed encouraging results as their therapeutic affects rival cisplatin. Keywords: Amino acids, organotin, Schiff base, fluorescent bioimaging, biogenic ligand, chiral Schiff base.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Drug Designing: Open Access.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalDrug Designing: Open Access
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Navjot S Batth”